Drug Type Small molecule drug |
Synonyms PG 011, PG-011, PG011 |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H20N8O2S |
InChIKeyOUXYFMCMGWQWQF-UHFFFAOYSA-N |
CAS Registry2401057-12-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 3 | CN | 19 Mar 2023 | |
Rhinitis, Allergic, Seasonal | Phase 2 | CN | 12 Jan 2024 | |
prurigo nodularis | Phase 2 | CN | 17 Dec 2021 | |
Rhinitis, Allergic | Phase 1 | CN | 05 Sep 2023 | |
Photosensitivity Disorders | Phase 1 | CN | - | |
Radiodermatitis | Phase 1 | CN | - | |
Epidermolysis Bullosa Pruriginosa | IND Approval | CN | 07 Oct 2023 | |
Nonsegmental vitiligo | IND Approval | CN | 29 Aug 2023 | |
Epstein-Barr Virus Infections | IND Application | CN | - | |
Epidermolysis Bullosa | Preclinical | US | 30 Jan 2022 |